Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
VIDEO LIBRARIES
Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
GRACE is excited to bring to you a new series on surviving with cancer. Our friend and partner, Raquel Jex Forsgren is the founder of Living Yoga Therapy based in Chicago, and is a certified oncology yoga therapist and resiliency coach. She brings us tips and techniques for those dealing with cancer.
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
GRACE is celebrating our 10 year anniversary! Dr. H. Jack West and the GRACE community have been helping each other since before that time but in this 10th year as a non-profit, we are pleased and humbled by the feedback and graciousness of those we have the pleasure to work with, and those who have found help and support through our GRACE site.
ARTICLES
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.
Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
Online Community
Hi, Question: Does anyone know of emerging research or clinical trials being done with ARID1A mutation for lung cancer here in US? History: I am stage...
In my continual education, I learned that the measure of PD-1 is an indication of likelihood of effectiveness of immunotherapy. The anecdotal belief...
Diagnosed with colon cancer Nov. 2016. Excellent response to chemo, radiation with no signs of tumor remaining. Opted to have colon resection, which...
Hi, I am in the uk and due to have to stop my pembro next week, not my choice but they will only let me have 35 cycles( 2 years) i was wondering if...
So I guess I’m just looking for a little feedback before I start scaring myself half to death. As of about December I started feeling a dull pain just...